November 16, 2020

How to Talk to Your Cancer Patients About Their COVID-19 Risk

Dr. Mikkael Sekeres in his latest New York Times column

650×450-Cleveland-Clinic-Cancer

Patients with cancer, and especially those receiving treatment, are approaching their physicians with questions about their risk of contracting COVID-19. Mikkael Sekeres, MD, MS, Director of Cleveland Clinic Cancer Center’s Leukemia Program, offers an expert’s perspective on the existing research in his latest New York Timescolumn. His answer to the question of whether cancer and chemotherapy increase the risk of death from COVID-19 provides a comprehensive look at existing research in patient-friendly language that can be a useful tool in communicating with your patients.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Read the column here.

Follow Dr. Sekeres on Twitter @MikkaelSekeres.

Related Articles

Hematologist at Cleveland Clinic
March 14, 2024
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Treating older patients with diffuse large B-cell lymphoma (DLBCL)
January 18, 2024
Trial for Patients 75 and Older with Diffuse Large B-Cell Lymphoma Helps Address Care Inequities

Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients

23-CNR-4221120 ASH 2023 Graphics-CQD
December 4, 2023
Ten ASH Presentations You Don’t Want to Miss

Cleveland Clinic oncologists’ selected abstracts

23-CNR-3741790-CQD-Hero-650×450 cell mobilization
April 24, 2023
Plerixafor is Effective for Hematopoietic Progenitor Cell Mobilization in Patients with AL Amyloidosis

On-demand stem cell mobilizer is an effective salvage strategy

CAR T-cell therapy
April 5, 2023
Insights About CAR T-Cell Therapy

Dispelling myths and sharing practical experiences

CAR T-cell therapy for multiple myeloma
March 13, 2023
Ide-CEL CAR T-Cell Therapy Effective in Multiple Myeloma Among Patients with Comorbidities

Research indicates strong rationale for expanding trial eligibility criteria

22-CNR-3245747-CQD-Hero-650×450 aplastic anemia
September 13, 2022
Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Retrospective study yields clues to understanding risk of secondary myeloid neoplasms

Ad